Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Authors: Gangaev A. et al.

Link to paper:

Journal/ Pre-Print: Research Square

Tags: Immunology/Immunity

Research Highlights 

1. CD8 T cell reactivity towards SARS-CoV-2 is common in COVID19 patients

2. 2 novel HLA-A*01:01 restricted epitopes from Orf1ab, TTD and PTD, defined, and confirmed importance of A2-restricted YLQ epitope

3. 3/9 epitopes identified yielded shared responses


In this paper, the authors investigated the SARS-Cov2 specific CD8 T cell responses in 22 severe/critical or recovered COVID-19 patients. Most of the SARS-Cov2 specific CD8 T cell responses were found in recovering (from severe disease) and severe patients (not critical). They are mostly reactive (and in a higher magnitude) toward ORF1ab protein and not the S protein which is the main target for vaccine design studies at the moment. Further CD8 T cell characterization showed that SARS-Cov2 specific CD8 T cells express higher levels of NKG2A than bulk CD8 T cells which needs further investigation.

Impact for SARS-CoV2/COVID19 research efforts

Understand the immune response to SARS-CoV2/COVID19: screen for epitope recognition in CD8 T cell response

Support for inclusion of a wider range of antigens (other than the S protein) in new vaccines to include a greater proportion of the CD8 response.

Study Type

· Clinical Cohort study (very small cohort for immune characterization)

Strengths and limitations of the paper

Novelty: Not only focused on S protein which is the current target for vaccine design. Used a tatramer-based approach to show that non-spike proteins (in particular ORF1ab) include epitopes that drive CD8 T cell responses in this cohort. Even if it is still unclear whether a strong CD8 T cell response have a protective role.

Standing in the field: Lower number of epitope and HLA coverage compared to other studies but used a tetramer approach.

Appropriate statistics: non-parametric statistical tests due to the very small sample size

Viral model used: hospitalized SARS-Cov2 infected patients

Translatability: Potentially diagnostic/prognostic

Main limitations:

- Relatively few epitopes screened

- Low number of patients and controls

- No data concerning clinical conditions and viral load of patients.

- The tetramer positive cells could have been more intensively phenotyped.